Pfiz­er emerges from pan­dem­ic cru­cible with con­fi­dence to go so­lo in tak­ing mR­NA vac­cines be­yond Covid-19

The pan­dem­ic has changed Pfiz­er.

It’s not just the $15 bil­lion in cash they ex­pect their BioN­Tech-part­nered Covid-19 vac­cine to bring in 2021. Rather, the phar­ma gi­ant is poised for a trans­for­ma­tion from a ma­jor part­ner in mR­NA tech­nol­o­gy to a ma­jor leader with its own de­vel­op­ment and man­u­fac­tur­ing ex­per­tise, with plans to grow the R&D team in Pearl Riv­er, NY by at least 50.

“We are the best po­si­tioned com­pa­ny right now to take it to the next step be­cause of our size and our ex­per­tise,” CEO Al­bert Bourla told the Wall Street Jour­nal in a sit-down in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER